Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for BRAF V600-mutant melanoma, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses to targeted therapy are almost universal but most are not durable, and resistance through MAPK reactivation has no approved answer.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Whether a short targeted-therapy induction before immunotherapy helps has not been settled in a phase 3 trial.
BRAF V600K and non-V600 mutations respond less well and have no dedicated drugs.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 26 changes by month →When this page itself was last checked or edited.
12-month EFS 83.
2-year OS 71.
A milestone in how this cancer is treated.
With atezolizumab and vemurafenib in BRAF V600 melanoma
Atezolizumab added to vemurafenib and cobimetinib prolonged investigator-assessed progression-free survival in BRAF V600-mutant melanoma, without an overall survival benefit; approved in July 2020.